Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Biocon
India - Bangalore
MICAFUNGIN SODIUM (micafungin) by Biocon is [see microbiology ()] . Approved for acute disseminated candidiasis, abscesses in adult, older [see clinical studies () and 6 more indications. First approved in 2025.
Drug data last refreshed 18h ago
[see Microbiology ()] .
Echinocandin Antifungal
Worked on MICAFUNGIN SODIUM at Biocon? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Micafungin Pharmacokinetics in Obese Patients
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo